Shares of Lupin were trading in the green and 2% higher on 15 January after the company announced receiving approval from the USFDA to market the generic hypertension drug.

In its regulatory filing, the company said, “Lupin. has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Propranolol Hydrochloride Extended-Release Capsules USP, 60 mg, 80 mg, 120 mg, and 160 mg, to market a generic equivalent of Inderal LA Extended- Release Capsules, 60 mg, 80 mg, 120 mg, and 160 mg, of ANI Pharmaceuticals, Inc.”

The drug will be manufactured at the company’s Pithampur facility in the country.

Propranolol hydrochloride extended-release capsules USP are indicated for the management of hypertension, to decrease angina and to treat prophylaxis of common migraine headaches.

Earlier this month, the company announced the launch of the Bromfenac ophthalmic solution, which is used for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery.

The company has also launched Varenicline tablets of 0.5 mg and 1 mg after the FDA nod. In December, the pharma company got the US regulator’s approval to market its generic loteprednol etabonate ophthalmic suspension for seasonal allergic conjunctivitis.

At 3:30 pm, Lupin’s shares closed 1.23% higher at Rs 1,415 on NSE.